Ocular Therapeutix will unveil topline data from its SOL-1 Phase 3 superiority trial evaluating AXPAXLI (OTX-TKI) for wet age-related macular degeneration on Tuesday, February 17, 2026. The trial represents a key regulatory milestone for the company's investigational tyrosine kinase inhibitor, which targets a significant therapeutic area affecting millions of patients globally.
Following the topline announcement, comprehensive trial results will be presented at the Macula Society Annual Meeting, providing the ophthalmic and investment communities with detailed efficacy and safety data. The presentation will allow for thorough analysis of AXPAXLI's performance relative to current standard-of-care treatments for wet AMD, a leading cause of vision loss in elderly populations.
The SOL-1 trial represents a critical juncture in the clinical development program for AXPAXLI, with potential implications for Ocular Therapeutix's portfolio and the broader retinal disease treatment landscape. The company's advancement of this candidate underscores the competitive activity in the wet AMD market, where alternative treatment modalities continue to evolve.